DEC 08, 2017 7:07 AM PST

Drug that Fights Alcoholism Also Fights Cancer

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

The drug that helps alcoholics kill their vice can also help kill cancer cells. And in a new study, researchers uncover the mechanism behind the anticancer effects of this anti-drinking drug, renewing the potential that this drug may someday be an option for cancer patients.

Known as disulfiram (trade name Antabuse), this drug is a potent inhibitor of acetaldehyde dehydrogenase, the enzyme responsible for metabolizing alcohol in the liver. When disulfiram is taken, any exposure to alcohol induces severe “hangover” symptoms, including flushing, throbbing headache, nausea, “copious vomiting,” and a slew of other unpleasant side effects, according to the manufacturer. So while disulfiram can’t be considered an antidote to alcoholism, it makes drinking so unpleasant as to help the person break their alcohol addiction.

But disulfiram has another power, killing cancer. Researchers have known this secondary effect since the 1970s – some studies have shown that disulfiram kills cancer in cells and in animal models. But how does this anti-drinking drug exert anti-cancer effects?

Researchers from the Danish Cancer Society Research Center in Copenhagen decided to pursue this hopeful path. They aimed find a link between disulfiram and survival in cancer patients. If indeed there is a link, they aimed to uncover the mechanisms behind disulfiram’s anticancer properties.

To answer their first aim, the team collected and analyzed data from over 3,000 Danish people who have been diagnosed with cancer. Mainly, they compared the survival of patients who took disulfiram after diagnosis versus those who stopped using the drug.

The team found an astonishing correlation: those who were on disulfiram after their cancer diagnosis had a 34 percent reduction in the risk of death from cancer, as compared to those who weren’t taking disulfiram. This protection seemingly applied to those suffering from colon, prostate, and breast cancers.

Taking the results even further, the team investigated disulfiram’s mechanisms in cancer cells and later in a mouse model. They landed on a key molecule, NPL4–p97, which promotes tumor growth. As it turns out, disulfiram immobilizes this protein, which consequently suppresses tumor growth.

“This paper solves a puzzle that has persisted in cancer research for decades,” said Michele Pagano, a cancer biologist at New York University who was not involved in the study.

Because disulfiram is an old drug, the road towards repurposing this drug for cancer treatment could be significantly shortened. And while pharmaceutical companies won’t exactly be clamoring for dibs (no patent protection, little financial incentive), the drug still holds a vast appeal for researchers, doctors, and cancer patients.

"Our results help to explain the anticancer activity of the alcohol-abuse drug disulfiram," said Jiri Bartek, the study’s senior author. "From a broader perspective, our study illustrates the potential of multifaceted approaches to drug repurposing, providing novel mechanistic insights, identification of new cancer-relevant targets, and encouragement for further clinical trials."

"[Disulfiram is] an old, safe, and public domain drug that might help to save lives of patients with cancer worldwide,” the team concluded.

Additional sources: Miami Herald, NatureMNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 13, 2020
Cell & Molecular Biology
JAN 13, 2020
Disrupting Leukemia's Deadly Reliance on Vitamin B6
Acute Myeloid Leukemia is a cancer of the blood that starts in the bone marrow, where the stem cells that produce blood cells reside, and rapidly moves to the blood....
JAN 20, 2020
Genetics & Genomics
JAN 20, 2020
Epigenetic Changes Make Breast Cancer Cells Drug Resistant
Researchers have found that changes in the structure of the genome in breast cancer cells can make them resistant to drug therapies....
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses agains...
FEB 17, 2020
Cancer
FEB 17, 2020
Listening in on cancer cells
Research published today in Nature Methods reports a new technique of “listening” to cancer cells. While it may sound odd (no pun intended...
FEB 19, 2020
Clinical & Molecular DX
FEB 19, 2020
Forget complicated scans - ovarian cancer can be detected in the blood
Results from clinical trials performed in Melbourne, Australia have revealed the diagnostic potential of a new test for ovarian cancer. Instead of using co...
Loading Comments...